Search
01/01/2023
Phase II trial of CDK4/6 inhibitor palbociclib in advanced sarcoma based on mRNA expression of CDK4/ CDKN2A
Martin-Broto J., Martinez-Garcia J., Moura D.S., Redondo A., Gutierrez A., Lopez-Pousa A., Martinez-Trufero J., Sevilla I., Diaz-Beveridge R., Solis-Hernandez M.P., Carnero A., Perez M., Marcilla D., Garcia-Foncillas J., Romero P., Fernandez-Jara J., Lopez-Lopez D., Arribas I., Hindi N.. Phase II trial of CDK4/6 inhibitor palbociclib in advanced sarcoma based on mRNA expression of CDK4/ CDKN2A. Signal Transduction and Targeted Therapy. 2023; 8(1)DOI:10.1038/s41392-023-01661-8. PMID:37875500. IF:40.800(Q1/1D).
01/01/2023
Endosomal escape for cell-targeted proteins. Going out after going in
Voltà-Durán E., Parladé E., Serna N., Villaverde A., Vazquez E., Unzueta U.. Endosomal escape for cell-targeted proteins. Going out after going in. BIOTECHNOLOGY ADVANCES. 2023; 63DOI:10.1016/j.biotechadv.2023.108103. PMID:36702197. IF:12.100(Q1/1D).
01/01/2023
Site-directed cysteine coupling of disulfide-containing non-antibody carrier proteins (THIOCAPs)
Rueda A., Mendoza J.I., Alba-Castellon L., Parladé E., Voltà-Durán E., Paez D., Aviño A., Eritja R., Vázquez E., Villaverde A., Mangues R., Unzueta U.. Site-directed cysteine coupling of disulfide-containing non-antibody carrier proteins (THIOCAPs). Science China-Materials. 2023; 66(10)DOI:10.1007/s40843-023-2571-6. PMID:. IF:6.800(Q1/3D).
01/01/2023
Machine Learning Improves Risk Stratification in Myelofibrosis: An Analysis of the Spanish Registry of Myelofibrosis
Mosquera-Orgueira, A, Perez-Encinas, M, Hernandez-Sanchez, A, Gonzalez-Martinez, T, Arellano-Rodrigo, E, Martinez-Elicegui, J, Villaverde-Ramiro, A, Raya, JM, Ayala, R, Ferrer-Marin, F, Fox, ML, Velez, P, Mora, E, Xicoy, B, Mata-Vazquez, MI, Garcia-Fortes, M, Angona, A, Cuevas, B, Senin, MA, Ramirez-Payer, A, Ramirez, MJ, Perez-Lopez, R, de Villambrosia, SG, Martinez-Valverde, C, Gomez-Casares, MT, Garcia-Hernandez, C, Gasior, M, Bellosillo, B, Steegmann, JL, Alvarez-Larran, A, Hernandez-Rivas, JM, Hernandez-Boluda, JC. Machine Learning Improves Risk Stratification in Myelofibrosis: An Analysis of the Spanish Registry of Myelofibrosis. Hemasphere. 2023; 7(1)DOI:10.1097/HS9.0000000000000818. PMID:36570691. IF:11.900(Q1/1D).
01/01/2023
Epigenome profiling reveals aberrant DNA methylation signature in GATA2 deficiency
Marin-Bejar O., Romero-Moya D., Rodriguez-Ubreva J., Distefano M., Lessi F., Aretini P., Liquori A., Castaño J., Kozyra E., Kotmayer L., Bueno C., Cervera J., Rodriguez-Gallego J.C., Nomdedeu J.F., Murillo-Sanjuán L., De Heredia C.D., Pérez-Martinez A., López-Cadenas F., Martínez-Laperche C., Dorado-Herrero N., Marco F.M., Prósper F., Menendez P., Valcárcel D., Ballestar E., Bödör C., Bigas A., Catalá A., Wlodarski M.W., Giorgetti A.. Epigenome profiling reveals aberrant DNA methylation signature in GATA2 deficiency. HAEMATOLOGICA. 2023; 108(9)DOI:10.3324/haematol.2022.282305. PMID:36815365. IF:10.100(Q1/2D).
01/01/2023
CINSARC in high-risk soft tissue sarcoma patients treated with neoadjuvant chemotherapy: Results from the ISG-STS 1001 study
Frezza A.M., Stacchiotti S., Chibon F., Coindre, JM, Italiano A., Romagnosa C., Bagué S., Dei Tos A.P., Braglia L., Palmerini E., Quagliuolo V., Broto J.M., Pousa, AL, Grignani G., Brunello A., Blay, JY, Beveridge R.D., Lugowska I., Lesluyes T., Maestro R., Merlo F.D., Casali P.G., Gronchi A.. CINSARC in high-risk soft tissue sarcoma patients treated with neoadjuvant chemotherapy: Results from the ISG-STS 1001 study. Cancer Medicine. 2023; 12(2)DOI:10.1002/cam4.5015. PMID:35848358. IF:2.900(Q2/5D).